Exercise reduces complications and improves function in frail elderly cancer patients on chemotherapy

This systematic review and meta-analysis examined the impact of exercise interventions on frail elderly cancer patients undergoing chemotherapy. The analysis pooled data from randomized controlled trials involving 1,655 patients aged 65 years or older who met standard diagnostic criteria for frailty. The specific clinical setting for the included trials was not reported. The population was defined by both age and frailty status, representing a particularly vulnerable group during cancer treatment.

The intervention consisted of structured exercise programs, while the comparator was conventional care without a formal exercise component. The review recommended comprehensive exercise programs combining aerobic and resistance training, administered 3 to 5 times weekly for 30 to 60 minutes over 8 to 12 weeks. The analysis emphasized that individualized protocols should be developed by multidisciplinary teams including oncology, rehabilitation, and geriatrics specialists, with dynamic tolerance assessment throughout the intervention period.

For primary outcomes, the meta-analysis did not explicitly report a single primary endpoint. However, among key efficacy measures, complication rates were significantly reduced with exercise compared to conventional care (OR = 0.41, P = 0.01). Severe complications were also significantly reduced (OR = 0.39, P = 0.003). The 12-minute walking distance showed improvement favoring exercise (MD = 45.64, P = 0.02). Fatigue decreased with exercise intervention (MD = -0.80, P = 0.002). Quality of life improved significantly (MD = -6.11, P < 0.001). Absolute numbers for these outcomes were not reported in the analysis.

Several secondary outcomes showed no significant effects. The Comprehensive Complication Index demonstrated no significant difference between exercise and conventional care groups (P > 0.05). Readmission rates similarly showed no significant effects (P > 0.05). Effect sizes for these non-significant outcomes were not reported. The direction of effects consistently favored exercise for outcomes showing statistical significance, while the non-significant outcomes showed no clear directional advantage for either group.

Safety and tolerability findings were notably limited in this meta-analysis. Adverse events, serious adverse events, discontinuation rates, and specific tolerability data were not reported. This represents a significant gap in the evidence, as safety considerations are particularly important when implementing exercise interventions in frail elderly patients undergoing chemotherapy, who may have multiple comorbidities and reduced physiological reserve.

These results contribute to a growing body of evidence supporting exercise during cancer treatment, though direct comparisons to prior landmark studies in this specific population are limited by the heterogeneity of exercise interventions and patient populations across trials. Previous research has generally supported the benefits of exercise in cancer patients, but this meta-analysis specifically focuses on the frail elderly subgroup, which has been less extensively studied. The findings align with broader principles of geriatric oncology that emphasize maintaining function during treatment.

Key methodological limitations include the authors' own acknowledgment that evidence remains limited. The meta-analysis did not report follow-up duration, which limits understanding of whether benefits persist beyond the intervention period. The specific clinical settings and exact exercise protocols varied across included trials, though the review provided general recommendations. Funding sources and potential conflicts of interest were not reported. The absence of safety data represents a significant limitation for clinical application.

Clinical implications suggest exercise can be recommended as a supportive therapy during chemotherapy for frail elderly patients, with particular attention to comprehensive programs combining aerobic and resistance training. The recommended frequency of 3 to 5 times weekly for 30 to 60 minutes over 8 to 12 weeks provides practical guidance, though individualization is essential. Multidisciplinary involvement from oncology, rehabilitation, and geriatrics specialists is recommended for protocol development and monitoring. Clinicians should note that while several outcomes improved, the Comprehensive Complication Index and readmission rates did not show significant benefits.

Important questions remain unanswered. The optimal exercise type, intensity, and progression for this population require further investigation. Long-term effects beyond the intervention period are unknown. Safety profiles and contraindications need clearer definition. The cost-effectiveness and practical implementation barriers in diverse healthcare settings warrant study. Whether benefits differ by cancer type, chemotherapy regimen, or frailty severity remains unclear. Future research should address these gaps with well-designed randomized trials including comprehensive safety monitoring.